SRC and ovarian cancer: We set out to investigate potential mechanisms of resistance to the SRC inhibitor saracatinib (AZD0530) in ovarian cancer, with the aim to highlight potential combination therapies and treatment stratification markers for SRC inhibitors in this disease.